These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 28194439)
21. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Kitko CL; Paczesny S; Yanik G; Braun T; Jones D; Whitfield J; Choi SW; Hutchinson RJ; Ferrara JL; Levine JE Biol Blood Marrow Transplant; 2008 Jul; 14(7):759-65. PubMed ID: 18541194 [TBL] [Abstract][Full Text] [Related]
22. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Leisenring WM; Martin PJ; Petersdorf EW; Regan AE; Aboulhosn N; Stern JM; Aker SN; Salazar RC; McDonald GB Blood; 2006 Jul; 108(2):749-55. PubMed ID: 16537799 [TBL] [Abstract][Full Text] [Related]
23. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease. Fiema B; Harris AC; Gomez A; Pongtornpipat P; Lamiman K; Vander Lugt MT; Paczesny S J Vis Exp; 2012 Oct; (68):. PubMed ID: 23149907 [TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Liu S; Han J; Gong H; Li Y; Bao X; Qi J; Liu H; Chen J; Wu X; Xu Y; Ma S; Wu D Sci Rep; 2018 Jul; 8(1):10328. PubMed ID: 29985424 [TBL] [Abstract][Full Text] [Related]
25. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]
26. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Ponce DM; Hilden P; Mumaw C; Devlin SM; Lubin M; Giralt S; Goldberg JD; Hanash A; Hsu K; Jenq R; Perales MA; Sauter C; van den Brink MR; Young JW; Brentjens R; Kernan NA; Prockop SE; O'Reilly RJ; Scaradavou A; Paczesny S; Barker JN Blood; 2015 Jan; 125(1):199-205. PubMed ID: 25377785 [TBL] [Abstract][Full Text] [Related]
27. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Russell JA; Duan Q; Chaudhry MA; Savoie ML; Balogh A; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA Biol Blood Marrow Transplant; 2008 Aug; 14(8):888-95. PubMed ID: 18640572 [TBL] [Abstract][Full Text] [Related]
28. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Srinagesh HK; Özbek U; Kapoor U; Ayuk F; Aziz M; Ben-David K; Choe HK; DeFilipp Z; Etra A; Grupp SA; Hartwell MJ; Hexner EO; Hogan WJ; Karol AB; Kasikis S; Kitko CL; Kowalyk S; Lin JY; Major-Monfried H; Mielke S; Merli P; Morales G; Ordemann R; Pulsipher MA; Qayed M; Reddy P; Reshef R; Rösler W; Sandhu KS; Schechter T; Shah J; Sigel K; Weber D; Wölfl M; Wudhikarn K; Young R; Levine JE; Ferrara JLM Blood Adv; 2019 Dec; 3(23):4034-4042. PubMed ID: 31816061 [TBL] [Abstract][Full Text] [Related]
29. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease. DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629 [TBL] [Abstract][Full Text] [Related]
30. A Day 14 Endpoint for Acute GVHD Clinical Trials. Spyrou N; Akahoshi Y; Kowalyk S; Morales G; Beheshti R; Aguayo-Hiraldo P; Al Malki MM; Ayuk F; Bader P; Baez J; Capellini A; Choe H; DeFilipp Z; Eder M; Eng G; Etra A; Gleich S; Grupp SA; Hexner E; Hoepting M; Hogan WJ; Kasikis S; Katsivelos N; Khan A; Kitko CL; Kraus S; Kwon D; Merli P; Portelli J; Qayed M; Reshef R; Schechter T; Vasova I; Wölfl M; Wudhikarn K; Young R; Holler E; Chen YB; Nakamura R; Levine JE; Ferrara JLM Transplant Cell Ther; 2024 Apr; 30(4):421-432. PubMed ID: 38320730 [TBL] [Abstract][Full Text] [Related]
31. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086 [TBL] [Abstract][Full Text] [Related]
32. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079 [TBL] [Abstract][Full Text] [Related]